読み込み中
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
前日終値
$18.15
+$0.41 · +2.31%
日中の時刻はETです。市場データは遅延する場合があります。
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
日中レンジ
現在 $18.15
52週レンジ
現在 $18.15
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
57
適正価値
センチメント
57
まちまち
リスク
47
やや高いリスク
モメンタム
85
強い上昇
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
日中レンジ
現在 $18.15
52週レンジ
現在 $18.15
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|
| 売上高 | 649.7万 USD | 148.7万 USD | — | — |
| 粗利益 | 649.7万 USD | 148.7万 USD | — | — |
| 研究開発 | 6745.1万 USD | 4095.4万 USD | 2591.9万 USD | 1430.2万 USD |
| 販売・一般管理 | 1259.8万 USD | 1130.7万 USD | 767.9万 USD | 510.6万 USD |
| 営業費用 | 8118.1万 USD | 5353.7万 USD | 3479.4万 USD | 1976.4万 USD |
| 受取利息 | 1100.9万 USD | 810.3万 USD | 537.7万 USD | 164.7万 USD |
| 減価償却費と償却費 | 232.9万 USD | 157.5万 USD | 112万 USD | 44.5万 USD |
| 営業利益 | −7468.4万 USD | −5205万 USD | −3479.4万 USD | −1976.4万 USD |
| 純利益 | −6373.1万 USD | −4398万 USD | −2864.1万 USD | −1792.9万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1516.08万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM1318.54万0.02%787.4億 USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI916.8万0.09%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF561.3万0.01%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO320.86万0.02%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO315.7万0.02%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA239.74万0.01%218.24億 USD0.03%$32.79+0.40%
Truth Social God Bless America ETFYALL116.69万1.42%8216.53万 USD0.65%$43.355+0.80%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHATruth Social God Bless America ETFYALLAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
